



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

CORRIGENDUM TO THE NOTICE OF EXTRAORDINARY GENERAL MEETING

Dear Members,

This is in reference to the Notice of Extraordinary General Meeting dated October 14, 2025 ("EGM Notice") of Chandan Healthcare Limited ("the Company") to be held on **Thursday, November 06, 2025, at 04:00 P.M. (IST), through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM)**, for seeking approval for matters contained in the said notice. The said notice has been duly dispatched to the shareholders of the Company as per the applicable laws. The Company, through this corrigendum, wishes to bring to the notice of the Shareholders of the Company the changes in the Resolutions/Explanatory Statement as set out for Item No. 2, contained in the EGM Notice, as follows:

I. REPLACEMENT OF THE NAME OF MR. RAVI KUMAR, APPEARING AT SERIAL NUMBER 9 OF THE TABLE PROVIDED IN PARA 1 OF THE RESOLUTION PROPOSED AT ITEM NO. 2 AND PARA I OF THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

The name of Mr. Ravi Kumar, appearing at serial number 9 of the table provided in para 1 of the resolution proposed at item no. 2 and para I of the explanatory statement provided for item no. 2, by Mr. Piyush Wadhwa.

II. CORRECTION OF THE RELEVANT DATE REFERRED TO IN PARA 2 OF THE RESOLUTION PROPOSED AT ITEM NO. 2 AND PARA E OF THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

The relevant date referred to in para 2 of the resolution proposed at item no. 2 and Para E of the Explanatory Statement provided for Item No. 2, may be read as Tuesday, October 07, 2025, instead of October 06, 2025.

III. REPLACEMENT OF PARA A (THE OBJECT/PURPOSE OF THE PREFERENTIAL ISSUE) TO THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

A. The object/purpose of the preferential issue:

The Company proposes to raise an amount aggregating up to Rs. 104,13,00,000/- (Rupees One Hundred Four Crore Thirteen Lakh Only) through the Preferential Issue. The proceeds of the Preferential Issue shall be utilized for will be deployed towards pursuing strategic business opportunities, facilitating the growth and expansion of the Company and for meeting general corporate purposes, as elaborated below:

a) Utilization of Net Proceeds



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

S. No.	Particulars	Total estimated amount to be utilized (INR In Crore)	Tentative timelines for utilization of net proceeds from the date of receipt of funds
1.	Business Expansion Business expansion by setting up new Diagnostics Labs and comprehensive Diagnostic centres	44,50,00,000	Within 2 Years from receipt of funds
2.	Acquisitions Acquisition of business units, existing diagnostic centres equipment's, labs, and other related assets	50,00,00,000	Within 2 Years from receipt of funds
3.	General Corporate Purpose	9,63,00,000	Within 2 Years from receipt of funds

Note: While the amounts proposed to be utilised against each of the objects have been specified above, there may be a deviation of 10% depending upon future circumstances, in terms of NSE notice No. NSE/ CML/2022/56 dated December 13, 2022, as the objects are based on management estimates and other commercial and technical factors. Accordingly, the same is dependent on a variety of factors such as financial, market and sectoral conditions, business performance and strategy, competition and other external factors, which may not be within the control of the Company and may result in modifications to the proposed schedule for utilization of the Issue Proceeds at the discretion of the Board, subject to compliance with applicable laws.

b) Interim use of Issue Proceeds

Our Company, in accordance with the approval of the Board from time to time, will have the flexibility to deploy the Issue Proceeds as an interim use of the same. Pending complete utilisation of the Issue Proceeds for the Objects described above, our Company intends to, inter alia, invest the Issue Proceeds in deposits in scheduled commercial banks, and any other investments as permissible under applicable laws.



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

c) Monitoring of utilisation of funds

- i. Given that the issue size exceeds Rs. 100 Crore (Indian Rupees One Hundred Crore), in terms of Regulation 162A of the SEBI ICDR Regulations, the Company has appointed Crisil Ratings Limited, a SEBI-registered Credit Rating Agency as the monitoring agency to monitor the use of the proceeds of the Preferential Issue ("Monitoring Agency").
- ii. The Monitoring Agency shall submit its report to the Company in the format specified in Schedule XI of the SEBI ICDR Regulations on a quarterly basis, till 100% (One Hundred Per cent) of the Issue Proceeds have been utilised. The Board and the management of the Company shall provide their comments on the findings of the Monitoring Agency in the format specified in Schedule XI of the SEBI ICDR Regulations. The Company shall, within 45 (forty-five) days from the end of each quarter, upload the report of the Monitoring Agency on its website and also submit the same to the Stock Exchanges.

IV. REPLACEMENT OF PARA D (THE PRICE AT WHICH THE ALLOTMENT PRICE IS PROPOSED AND THE BASIS ON WHICH THE PRICE HAS BEEN ARRIVED AT) TO THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

The Equity Shares of the Company are listed on the Stock Exchange i.e. National Stock Exchange (NSE), viz. National Stock Exchange of India Limited and are frequently traded in accordance with the ICDR Regulations.

The Floor Price at which Equity Shares shall be allotted shall not be less than the higher of the following.

- a. The 90 (Ninety) trading days volume weighted average price of the Equity Shares of the Company quoted on the NSE, preceding the Relevant Date, i.e. Rs. 221.71 (Rupees Two Hundred Twenty-One and Seventy-One Paise Only) per Equity Share;
- b. The 10 (Ten) trading days volume weighted average price of the Equity Shares of the Company quoted on the NSE, preceding the Relevant Date, i.e. Rs. 233.28 (Rupees Two Hundred Thirty-Three and Twenty-Eight Paise Only) per Equity Share.

Accordingly, the floor price in terms of Regulation 164 of the ICDR Regulation is Rs. 233.28 (Rupees Two Hundred Thirty-Three and Twenty-Eight paise only) per Equity Share, being the higher of the above two prices.

It is hereby confirmed that as per the first proviso to Regulation 164(1) the Articles of Association of the Company does not provide for a method of determination which results in a floor price higher than that determined under these regulations.

Regulation 166A of the SEBI ICDR Regulations mandates that any preferential issue, which may result in a change in control or allotment of more than five per cent. of the post issue fully diluted share capital of the issuer, to an allottee or to allottees acting in concert, shall require a valuation



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

report from an independent registered valuer and consider the same for determining the price. Accordingly, the Company has obtained a report from the Independent Registered Valuer.

The higher of the floor price determined as per Regulation 164(1) of the SEBI ICDR Regulations and the price determined by the Independent Registered Valuer as per Regulation 166A of the SEBI ICDR Regulations, ie. Rs. 233.28/- has been considered as the minimum price for the Preferential issue.

A certificate is obtained from Akshat Garg & Associates, Company Secretaries, confirming the minimum price for the preferential issue as per the Preferential Issue Regulations in Chapter V of SEBI ICDR Regulations, 2018 and showing the calculation thereof, and the same is available at the website of the Company at the weblink:

https://chandandiagnostic.com/admin/uploads/Chandan%20Healthcare_Preferential%20Issue_PCS%20Certificate_25.10.2025.pdf

In terms of the provisions of Regulation 166A of the SEBI ICDR Regulations, the price has been determined by the Valuation Report issued by the Independent Registered Valuer through the Valuation Report, issued by Mr. Siddharth Gupta, Registered Valuer, (IBBI Reg. No. IBBI/RV/05/2019/11261). The said report is available on the website of the Company at the weblink:

https://chandandiagnostic.com/admin/uploads/Chandan%20Healthcare_Preferential%20Issue_PCS%20Certificate_25.10.2025.pdf

The Board of Directors of the Company, in their meeting held on Friday, October 10, 2025, has accordingly decided the issue price as Rs. 234/-, which is not below the minimum price determined as per SEBI ICDR Regulations.

V. REPLACEMENT OF PARA G (THE INTENTION / PROPOSAL OF THE PROMOTERS, DIRECTORS AND KEY MANAGERIAL PERSONNEL OF THE COMPANY TO SUBSCRIBE TO THE PROPOSED PREFERENTIAL OFFER) TO THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

The following persons from the Promoter and Promoter Group have expressed their intention to subscribe to any shares pursuant to this preferential issue of equity shares:

1. Mr. Amar Singh (Managing Director & Promoter)
2. Mrs. Asmita Singh (Managing Director & Promoter)
3. Mr. Anant Singh (Promoter Group)
4. Mrs. Aasti Singh (Promoter Group)
5. Mr. Shailendra Singh (Promoter Group)

None of the Directors, Promoters or Key Managerial Personnel other than the above-mentioned persons from the Promoter and Promoter Group intends to subscribe to any shares pursuant to this preferential issue of equity shares.

VI. CORRECTION IN THE 30-DAY TIME MENTIONED IN PARA H (PROPOSED TIME WITHIN WHICH THE ALLOTMENT SHALL BE COMPLETED) TO THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

The proposed time within which the allotment shall be completed, referred to in para H of the Explanatory Statement provided for Item No. 2, may be read as 15 (fifteen) days instead of 30 (thirty) days.



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

VII. AMENDMENT IN PARA Q (PRACTISING COMPANY SECRETARY CERTIFICATE) TO THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

The following text is added in in para Q (practicing company secretary certificate) to the explanatory statement provided for item no. 2.

Practising company secretary certificate confirms that the entire pre-preferential holding of the proposed allottees is in dematerialized form, in compliance with Regulation 163(2) of Chapter V of the SEBI (ICDR) Regulations, 2018.

The Valuation Report and the Certificate from the Practising Company Secretary are available on the Company's website for inspection at the following links:

Valuation Report	https://chandandiagnostic.com/admin/uploads/Final%20Signed%20Report%20RV.pdf
PCS Certificate	https://chandandiagnostic.com/admin/uploads/Chandan%20Healthcare_Preferential%20Issue_PCS%20Certificate_25.10.2025.pdf

VIII. INSERTION OF NEW PARA U (ULTIMATE BENEFICIAL OWNER OF THE PROPOSED ALLOTTEES) TO THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

U. Ultimate Beneficial Ownership (UBO) of the Proposed Allottees:

The Ultimate Beneficial Owners (UBO) of the proposed allottees are as follows:

S r. No.	Name of Proposed Allottee	Status	Category	Pre-Preferential Holding (No. of shares)	% of Pre Holding	No. of Warrants to be Issued	Post-Issue Holding (No. of shares)	% of Post Holding	Ultimate Beneficial Owner
1.	Jeena Sikho Lifecare	Body Corpora	Non-Promote	0	0	18,00,000	18,00,000	6.23	Manish Grover



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

	Limited	te	r						
2.	Amar Singh	Individu al	Pro mote r & MD	23,29,460	9.53	3,50,000	26,79,460	9.27	N/A
3.	Negen Undiscov ered Value Fund	AIF	Non-Pro mote r	7,73,600	3.16	4,00,000	11,73,600	4.06	Neil Madan Bahal
4.	Negen Capital Services Pvt. Ltd.	Body Corpora te	Non-Pro mote r	0	0	2,50,000	2,50,000	0.86	Neil Madan Bahal
5.	Compact Structure Fund	AIF	Non-Pro mote r	0	0	3,50,000	3,50,000	1.21	1. Vijay Bhatia: AAOPB43 06J 2. Brajesh Parekh: AEUPP38 25L 3. Jitendra Sanghavi: APSPS978 7H
6.	Rashmi Sharma	Individu al	Non-Pro mote r	0	0	4,00,000	4,00,000	1.38	N/A
7.	Jai Goyal	Individu al	Non-Pro mote r	0	0	2,00,000	2,00,000	0.69	N/A
8.	Reshma Panwar	Individu al	Non-Pro mote r	0	0	2,00,000	2,00,000	0.69	N/A
9.	Piyush Wadhwa	Individu al	Non-Pro mote r	0	0	100000	100000	0.35	N/A



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

10.	Divya Hitesh Rambhia	Individual	Non-Pro moter	4,800	0.02	1,00,000	1,04,800	0.36	N/A
11.	Aman Walia	Individual	Non-Pro moter	0	0	1,00,000	1,00,000	0.35	N/A
12.	Nishith Sadh	Individual	Non-Pro moter	0	0	44,000	44,000	0.15	N/A
13.	Divya Varshney	Individual	Non-Pro moter	14,400	0.06	40,000	54,400	0.19	N/A
14.	Shailendra Singh	Individual	Pro moter Group	0	0	25,000	25,000	0.09	N/A
15.	Asmita Singh	Individual	Pro moter & MD	1,67,600	0.68	25,000	1,92,600	0.67	N/A
16.	Anant Singh	Individual	Pro moter Group	1,09,800	0.45	25,000	1,34,800	0.47	N/A
17.	Aasti Singh	Individual	Pro moter Group	74,800	0.31	25,000	99,800	0.35	N/A
18.	Rajnish Varshney	Individual	Non-Pro moter	0	0	16,000	16,000	0.06	N/A
	Total			34,74,460	14.21	44,50,000	7924460	27.43	



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

It is also confirmed that:

- The Company has obtained the details of the ultimate beneficial owners of non-individual proposed allottees.
- The Company has obtained and verified the details of the Permanent Account Number (PAN) of each of the Proposed Allottees.
- All proposed allottees (Promoter and Promoter Group) are deemed as acting in concert with the Promoter and Promoter Group, as summarized below:
- None of the above Proposed Allottees (Non-Promoter), except as mentioned below, is acting in concert with any other Allottee(s):
 - Negen Undiscovered Value Fund and Negen Capital Services Pvt. Ltd.

IX. INSERTION OF NEW PARA V (SHAREHOLDING PATTERN (PRE AND POST PREFERENTIAL ISSUE) TO THE EXPLANATORY STATEMENT PROVIDED FOR ITEM NO. 2

A statement showing the shareholding pattern of the Company before and after the proposed preferential issue is as follows:

Shareholding Pattern (Pre and Post Preferential Issue)

Sr N o	Category of Shareholder(s)	Pre-Issue		Allo tme nt of War rant s	Post – Issue (Post exercise of Warrants into Equity Shares)	
		(as on October 10, 2025)			No. of shares held	*% of share holding
		No. of Shares held	% of share holding			
A	Promoters & Promoter Group Holding					
1	Indian					
a)	Individual	79,67,620	32.58	4,50,000	84,17,620	29.12
b)	Family Trust	0	0.00	0	0	0.00
c)	Bodies Corporate	4128064	16.88	0	4128064	14.28
	Sub-Total (A)(1)	1,20,95,684	49.47	4,50,000	1,25,45,684	43.41
2	Foreign					
a)	Individual	0	0.00	0	0	0.00
b)	Bodies Corporate	0	0.00	0	0	0.00
	Sub- Total (A)(2)	0	0.00	0	0	0.00
	Total Promoters & Promoter Group Holding (A)	1,20,95,684	49.47	4,50,000	1,25,45,684	43.41
B	Non-Promoters Holding					
1	Institutional Investors	0	0.00		0	0.00
a)	Mutual Funds	0	0.00		0	0.00



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

b)	Alternate Investment Funds	1257600	5.14	7,50,000	2007600	6.95
c)	Foreign Portfolio Investors / foreign body corporate	131200	0.54	0	131200	0.45
d)	Financial Institutions/ Banks	0	0.00	0	0	0.00
e)	Insurance Companies	0	0.00	0	0	0.00
	Sub-Total (B)(1)	1388800	5.68	7,50,000	2138800	7.40
2	Central Government/ State Government	0	0.00	0	0	0.00
	Sub-Total (B)(2)	0	0.00	0	0	0.00
3	Non-Institutions					
a)	Individuals					
i)	Individual shareholders holding nominal share capital upto Rs. 2 lakhs	17,41,000	7.12	16,000	17,57,000	6.08
ii)	Individual shareholders holding nominal share capital in excess of Rs. 2 lakhs	73,34,580	30.00	11,84,000	85,18,580	29.47
b)	NBFCs registered with RBI	0	0.00	0	0	0.00
c)	Any other, specify					
	Foreign National	0	0.00	0	0	0.00
	Hindu Undivided Family	2,00,000	0.82	0	2,00,000	0.69
	Non-Resident Indians	3,57,600	1.46	0	3,57,600	1.24
	Clearing Member	0	0.00	0	0	0.00
	Body Corporate	13,34,400	5.46	20,50,000	33,84,400	11.71
	Sub-Total (B)(3)	1,09,67,580	44.85	32,50,000	1,42,17,580	49.19
	Total Public Shareholding (B)	1,23,56,380	50.53	40,00,000	1,63,56,380	56.59
	Total (A)+(B)	2,44,52,064	100.00	44,50,000	2,89,02,064	100.00
C	Shares held by custodians for ADR and GDR	0	0.00	0	0	0.00
	Total (A)+(B)+(C)	2,44,52,064	100.00	44,50,000	2,89,02,064	100.00

Summary of Category wise Pre and Post Shareholding Pattern

Sr. No.	Description	Pre-Issue Shareholding		Post-Issue Shareholding	
		Total Shares	% Equity	Shares	*% Equity



CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: U85110UP2003PLC193493

TEL NO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

1	Promoters	10309324	42.1614	10709324	37.05384
2	Promoter group	1786360	7.3056	1786360	6.180735
3	Public	12356380	50.533	16406380	56.76543
	Total	24452064	100	2,89,02,064	100

* Percentage of Post Preferential Issue is assuming full conversion of Warrants within 18 months from the date of allotment.

(Figures are illustrative and proportionate to the total equity capital post-conversion of 44,50,000 warrants. Actual shareholding will be adjusted upon final allotment.)

Note:

1. This Corrigendum shall form an integral part of the EGM Notice and should be read in conjunction therewith.
2. All other contents, terms, and conditions of the EGM Notice dated October 14, 2025, shall remain unchanged.
3. This Corrigendum and updated EGM Notice are available on the Company's website at www.chandandiagnostic.com and the websites of the stock exchanges where the Company's shares are listed.

For and on behalf of the Board of Directors
CHANDAN HEALTHCARE LIMITED

Rajeev Kumar Nain

Company Secretary & Compliance Officer

Place: Lucknow

Date: October 31, 2025